Consolidative Ipilimumab and Nivolumab With Thoracic Radiotherapy After Platinum Based Chemotherapy for Patients With Extensive-Stage Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 May 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 May 2018 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.
- 10 May 2018 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2017 Status changed from not yet recruiting to recruiting.